The drugs manufacturing industry is on a state of alert following two landmark developments over a cancer treatment medicine.
Pharma major Roche Scientific Company on Tuesday launched its revolutionary anti-cancer drug 'Tarceva' (erlotinib), which 'prolongs and improves' quality of the life of patients, suffering from lung cancer.\n\n
'Pay-for-delay' settlements between drug patent-holders and generics manufacturers to delay the launch of cheaper generic medicine are increasingly being scrutinised by antitrust regulators
